Ocular sees Axpali’s potential for durable activity

17 June 2024

Ophthalmology specialist Ocular Therapeutix (Nasdaq: OCUL) has highlighted impressive clinical development progress with Axpali (axitinib intravitreal implant) for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR) at an investor day.

The Massachusetts, USA, firm provided three updates on the product candidate for retinal disease, leading shares in the company to close 14% higher on Friday.

"2024 has been a time of significant accomplishment for Ocular"Firstly, Ocular has reported excellent enrollment in the Phase III Axpali SOL-1 study with 60 study sites active and 151 subjects enrolled in various stages of loading and randomization as of June 7, reflecting strong investigator engagement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK